Having an investor turn down your transaction is discouraging, particularly when your Med Tech company has created an attractive offering, recruited an experienced team, and found an unmet clinical need. But not receiving a “go” from an investor does not necessarily mean your business has no merit.

Investment decisions are driven by factors such as portfolio composition, company lifecycle stage, clinical data, market opportunity and risk appetite. It is helpful for founders to know what factors contribute to the reasons for feedback and when it may be an investor’s lack of fit.

Through LSI Europe, founders can engage with investors and industry professionals to better understand investment expectations and identify partners whose interests align with their company’s development.

Investment Rejections Often Reflect Portfolio Fit

Venture capital firms process hundreds of ideas but make relatively few investments. A strong technology and management team may not be in a firm’s investment focus.
The investor could also be interested in investing in companies in a particular stage of development, or in specific geographic regions, or in certain clinical areas. If the fund already has significant investment in cardiovascular devices, it might not want to invest in any additional companies in that sector.
It does not mean, necessarily, that the new opportunity is poor; it could be something that, for the moment at least, does not measure up against what the investor currently considers important.

Founders should therefore evaluate investor alignment before beginning an extensive fundraising process. Industry gatherings such as LSI Europe can help entrepreneurs connect with investors whose interests better match their technology, development stage, and commercial objectives.

How Portfolio Strategy Influences Investment Decisions

Investors consider each opportunity against the backdrop of their current investments and broader investment goals, asking themselves whether a company fits with their portfolio and whether its potential investment returns outweigh its risks.

Common evaluation factors include:

• Strength and maturity of clinical evidence.
• Complexity of the regulatory pathway.
• Size and accessibility of the target market.
• Progress toward commercial readiness.
• Geographic exposure and market conditions.
• Existing investments in similar technologies or clinical areas.

This is why two investors can see the same company differently. One sees it as an appealing candidate for a new portfolio, and another who sees it as merely a duplicate of the investments he already owns.
Founders will now be able to strategically approach investment prospects instead of feeling downbeat every time it turns down an investment.

Investment Timing Can Change the Outcome

Med Tech Companies can go through various development phases such as early engineering, preclinical testing, clinical testing, regulatory submissions, and commercialization.
Investors may be at different stages of the curve. Some are willing to participate in the very early, pre-clinical stages while others look for more robust clinical data, moving forward through regulatory approval and initial customer adoption.
Today, if a company is not a suitable investment for an investor, it may be more compelling after it accomplishes other benchmarks.
Founders should have positive engagement with potential investors who pass and are interested in the technology. Regular updates about clinical data, regulatory, customer validation, and commercial findings provides a reason to revisit discussions.

Turn Investor Questions Into Useful Feedback

Even if the meeting does not lead to an investment, it can shed light on what areas need further exploration.
Questions from investors may focus on clinical data, the company’s regulatory approach, reimbursement, demand in the market, or the business development model.
The founders should analyze the fundamental issue instead of treating every objection as a step to change direction.
For instance, inquiries concerning clinical data might suggest that the evidence to support the claims of product benefit requires strengthening, whereas there might be queries about market demand which could be driven by insufficient customer insight or lack of clarity regarding purchase.
Likewise, reimbursement unawareness may expose shortcomings in the company’s access to the market plan.
If founders keep hearing the same questions from investors at their meetings, they’ll learn how to get better with their next presentation.

Build Investor Relationships Before the Next Round

Fundraising is stronger when it is viewed as a relationship, not a checkbook.
Longtime investors have the advantage of knowing a company’s track record, which can help them better understand who’s in charge, how a company executes, and how it reacts when adversity hits.

Industry events and partnering opportunities can help founders maintain these connections. LSI USA and LSI Europe connect participants across the medical technology ecosystem, creating opportunities to meet investors, strategic companies, and other decision makers.

These relationships may support future financing discussions, commercial partnerships, or strategic opportunities as a company matures.

Demonstrate Progress Through Meaningful Milestones

Concretizing your investment case is one of the most powerful ways to make it more compelling.
Depending on the stage of the company, significant milestones could include achieving technical validation, passing clinical studies, obtaining regulatory approval, early adoption by customers, or seeing a viable commercial model emerge.
The importance of each milestone varies depending on the technology and the company’s goals. The founder should specify how each completed milestone addresses and minimizes risk, and moves the company toward commercialization.

Moon Surgical provides a relevant example of a medical device company progressing through regulatory development, with the linked coverage discussing FDA clearance for a commercial version of its Maestro system.

For other emerging Medtech businesses, the central lesson is to connect technical and clinical progress to a clear investment rationale.

A Practical Strategy for Responding to a Pass

After an investor declines an opportunity, founders can follow a structured approach.

First, clarify the reason. Ask whether the decision reflects investment stage, portfolio fit, market concerns, or a specific business risk.

Second, evaluate the feedback. Separate concerns that can be addressed through stronger evidence or planning from factors outside the company’s control.

Third, refine investor targeting. Prioritize firms and other investors whose investment interests align with the company’s current stage.

Fourth, communicate future progress. Share relevant updates when the company achieves meaningful milestones.

Finally, strengthen the investment narrative. Ensure the pitch clearly explains the unmet clinical need, supporting evidence, market opportunity, funding requirements, and next milestones.

Looking Ahead

One investor rejection does not determine the death of a Med Tech company. Investments are impacted by where the pipeline is in terms of portfolio strategy, development, timing, and perceived risk.
Knowing these insights can help founders leverage feedback from investors, optimize their approach to raising capital, and develop relationships that could prove useful as the company continues to grow.
Forum for founders To meet investors and strategic companies to discover insights into the industry, form partnership opportunities and locate funding relationships that fit their goals.